Tempus AI (NASDAQ:TEM) Price Target Raised to $92.00

Tempus AI (NASDAQ:TEM) had its price target upped by Robert W. Baird from $85.00 to $92.00 in a report issued on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research analysts also recently commented on TEM. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th. Raymond James Financial set a $80.00 price target on shares of Tempus AI in a research note on Wednesday, September 2nd. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. BTIG Research upped their price objective on shares of Tempus AI from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Canaccord Genuity Group raised their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Eleven equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of “Hold” and an average target price of $79.37.

Tempus AI Stock Performance

Shares of TEM opened at $70.43 on Tuesday. The stock has a 50 day moving average price of $71.21 and a 200 day moving average price of $57.20. The company has a quick ratio of 3.16, a current ratio of 2.61 and a debt-to-equity ratio of 2.70. The company has a market capitalization of $12.71 billion, a price-to-earnings ratio of -66.44 and a beta of 3.61. Tempus AI has a 52-week low of $40.77 and a 52-week high of $89.09.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The company had revenue of $411.54 million for the quarter, compared to analysts’ expectations of $409.39 million. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The firm’s revenue for the quarter was up 23.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.46) earnings per share. Research analysts predict that Tempus AI will post -1.45 EPS for the current fiscal year.

Insider Activity at Tempus AI

In related news, EVP Andrew Polovin sold 22,148 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the sale, the executive vice president owned 146,067 shares of the company’s stock, valued at approximately $7,246,383.87. The trade was a 13.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $2,038,722.95. Following the completion of the transaction, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at $27,903,789.43. The trade was a 6.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 1,237,227 shares of company stock valued at $85,388,983. Company insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TEM. V Square Quantitative Management LLC purchased a new stake in Tempus AI in the 3rd quarter valued at approximately $27,000. EMC Capital Management purchased a new position in Tempus AI during the second quarter worth $29,000. Ulland Investment Advisors LLC purchased a new position in Tempus AI during the third quarter worth $41,000. Heritage Family Offices LLP acquired a new position in shares of Tempus AI in the third quarter worth $45,000. Finally, Eastern Bank acquired a new position in shares of Tempus AI in the third quarter worth $69,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Cantor Fitzgerald maintained its Buy rating, while HC Wainwright and Robert W. Baird were also reported to see strong potential appreciation. These recommendations may support investor confidence. Cantor Fitzgerald maintains Buy rating HC Wainwright forecast Baird forecast
• Positive Sentiment: Recent results were stronger than expected: Tempus reported quarterly revenue of $411.5 million, up 23.1% year over year, and earnings per share of $0.07 versus analysts’ forecast for a loss. The beat provides a favorable business-performance backdrop. Tempus AI earnings beat
• Negative Sentiment: CEO Ryan Fukushima sold 80 shares and director David Epstein sold 370 shares at $74.29. Both trades were executed under pre-arranged Rule 10b5-1 plans, and the small sales leave their substantial holdings largely intact, tempering the potential concern. Director stock sale disclosure

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.